Genomic sequencing analysis of 733 HER2-amplified primary and metastatic breast tumours discovered sizeable enrichment of mutations that activate RAS–MAPK signalling in advanced tumours treated with prior anti-HER2 therapies121. These mutations, including NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. Figuring out much more about your cancer https://www.directivepublications.org/journal-of-clinical-breast-cancer/